MX9306196A - Nueva forma cristalina polimorfa de terazosina y composicion farmaceutica que la contiene. - Google Patents

Nueva forma cristalina polimorfa de terazosina y composicion farmaceutica que la contiene.

Info

Publication number
MX9306196A
MX9306196A MX9306196A MX9306196A MX9306196A MX 9306196 A MX9306196 A MX 9306196A MX 9306196 A MX9306196 A MX 9306196A MX 9306196 A MX9306196 A MX 9306196A MX 9306196 A MX9306196 A MX 9306196A
Authority
MX
Mexico
Prior art keywords
terazosine
pharmaceutical composition
crystal form
new crystal
form polymorph
Prior art date
Application number
MX9306196A
Other languages
English (en)
Inventor
Glenn A Meyer
John F Bauer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9306196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX9306196A publication Critical patent/MX9306196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una nueva forma polimorfa cristalina anhidra del monoclorhidrato de la 1-(4-amino-6,7-dimetoxi-2-quinazolinil)-4-(2-tetra hidrofuroil)piperazina, junto con las formulaciones farmacéuticas que contienen el compuesto. La nueva forma poliforma exhibe un efecto alimenticio disminuido cuando se administra a seres humanos.
MX9306196A 1993-04-29 1993-10-05 Nueva forma cristalina polimorfa de terazosina y composicion farmaceutica que la contiene. MX9306196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5491793A 1993-04-29 1993-04-29
US08/090,721 US5294615A (en) 1993-04-29 1993-07-13 Terazosin polymorph and pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX9306196A true MX9306196A (es) 1994-01-31

Family

ID=26733641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306196A MX9306196A (es) 1993-04-29 1993-10-05 Nueva forma cristalina polimorfa de terazosina y composicion farmaceutica que la contiene.

Country Status (9)

Country Link
US (2) US5294615A (es)
EP (1) EP0623612B1 (es)
JP (1) JP2755895B2 (es)
DE (1) DE69300913T2 (es)
DK (1) DK0623612T3 (es)
ES (1) ES2089665T3 (es)
GR (1) GR3018433T3 (es)
HK (1) HK124397A (es)
MX (1) MX9306196A (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596109A (en) * 1992-03-24 1997-01-21 Smithkline Beecham Corporation N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph A
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
ATE353892T1 (de) * 1996-12-20 2007-03-15 Heumann Pharma Gmbh & Co Neue polymorphe form von doxazosinmesylat (form iii)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
KR20060093355A (ko) * 1999-08-03 2006-08-24 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
ATE405577T1 (de) * 2000-11-17 2008-09-15 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
TWI353979B (en) 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US7097967B2 (en) * 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
WO2008021891A2 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
CN102321563B (zh) 2011-10-24 2013-04-03 江南大学 一株拟无枝酸菌及利用其全细胞转化制备香草醛的方法
US9096428B2 (en) * 2013-03-08 2015-08-04 Taiwan Semiconductor Manufacturing Company, Ltd. Methods and apparatus for MEMS structure release
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法

Also Published As

Publication number Publication date
JPH06312984A (ja) 1994-11-08
JP2755895B2 (ja) 1998-05-25
EP0623612A1 (en) 1994-11-09
DE69300913T2 (de) 1996-05-02
ES2089665T3 (es) 1996-10-01
DE69300913D1 (de) 1996-01-11
HK124397A (en) 1997-09-12
DK0623612T3 (da) 1996-02-05
EP0623612B1 (en) 1995-11-29
GR3018433T3 (en) 1996-03-31
US5362730A (en) 1994-11-08
US5294615A (en) 1994-03-15

Similar Documents

Publication Publication Date Title
MX9306196A (es) Nueva forma cristalina polimorfa de terazosina y composicion farmaceutica que la contiene.
DOP2011000109A (es) Un compuesto seleccionado del acido 6-(-4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5- carboxilico (2-hidroxi-etoxi)- amida y sales farmaceuticamente aceptables del mismo, y composiciones farmaceuticas que contienen dicho compuesto
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
CY1112671T1 (el) Σταθερο πολυμορφο υδροχλωρικης ν-(3-αιθυνυλφαινυλαμινο)-6,7-δις(2-μεθοξυαιθοξυ)-4-κιναζολιναμινης, μεθοδοι παραγωγης, και φαρμακευτικες χρησεις αυτης
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
PA8447001A1 (es) Atropisomeros de 3- aril-4(3h)- quinazolinonas
PA8463901A1 (es) Compuestos azapoliciclicos condensados con arilo
BR0207726A (pt) Sais farmacêuticos
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
ES2062943B1 (es) Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
GT199700049A (es) Nueva 4(3h)-quinazolinonas 2,3 disustituidas
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
GT199800039A (es) Atropisomeros de 3-heteroaril-4(3h)-quinazolinonas.
CO5570673A2 (es) Compuestos azapoliciclicos condensados con arilo
PE20040899A1 (es) Profarmaco inhibidor de beta-lactamasa
GEP20074051B (en) Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
PE9296A1 (es) Forma polimorfica cristalina de (s,s,s)- n- (1-[ 2- carboxi- 3-(n�- mesil- lisilamino) propil]- 1-ciclopentil carbonil )tirosina (forma o) y procesos de obtencion
PA8496101A1 (es) Formas polimorfas de un citrato de azobiciclo (2.2.2)octan-3-amina y sus composiciones farmaceuticas
HN2002000354A (es) Sales de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen
UY27568A1 (es) Forma de fármaco cristalina
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
ATE295845T1 (de) Prucaloprid-n-oxid

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees